43. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010; 52: 1156–61.
44. Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of nonalcoholic fatty liver disease. AlimentPharmacol Ther 2008; 28: 503–22.
45. Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol Res 2009; 39: 213–22.
46. Bedogni G, Bellentani S, Miglioli L. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.
47. Gastaldelli A, Kozakova M, Hojlund K. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537–44.
48. de Andrade AR, Cotrim HP, Alves E. Nonalcoholic fatty liver disease in severely obese individuals: the influence of bariatric surgery. Ann Hepatol 2008; 7: 364–8.
49. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 2010; 10: 56.
50. Palmentieri B, de Sio I, La Mura V. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. DigLiver Dis 2006; 38: 485–9.
51. Mottin CC, Moretto M, Padoin AV. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004; 14: 635–7.
52. Saadeh S, Younossi ZM, Remer EM. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745–50.
53. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007; 189: W320–3.
54. Hubscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology 2006; 49: 450–65.
55. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005; 42: 928–40.
56. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664–9.
57. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74–80.
58. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689–92.
59. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349–54.
60. Bugianesi E. Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol Ther 2005; 22(Suppl. 2): 40–3.
61. Bullock RE, Zaitoun AM, Aithal GP, Ryder SD, Beckingham IJ, Lobo DN. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J Hepatol 2004; 41: 685–6.
62. Paradis V, Zalinski S, Chelbi E. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009; 49: 851–9.
63. Kleiner DE, Brunt EM, Van Natta M. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
64. Vernon G; Baranova A; Younossi Z.M. The Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis in Adults. Alimentary Pharmacology & Therapeutics. 2011;34(3):274-285.
65. Ratziu V, Charlotte F, Heurtier A. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898–906.
66. Janiec DJ, Jacobson ER, Freeth A, Spaulding L, Blaszyk H. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg 2005; 15: 497–501.
67. Angulo P, Hui JM, Marchesini G. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846–54.
68. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441–7.
69. Ruffillo G, Fassio E, Alvarez E. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011; 54: 160–3.
70. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265–9.
71. Raszeja-Wyszomirska J, Szymanik B, Lawniczak M. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 2010; 10: 67.
72. Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Applicability of BARD score to Japanese patients with NAFLD. Gut 2009; 58: 1566–7.
73. Wai CT, Greenson JK, Fontana RJ. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518–26.
74. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95: 734–9.
75. Vallet-Pichard A, Mallet V, Nalpas B. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32–6.
76. Cales P, Laine F, Boursier J. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50: 165–73.
77. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008; 7: 350–7.
78. Fujii H, Enomoto M, Fukushima W. Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol 2009; 44: 608–14.
79. Neuschwander-Tetri BA, Clark JM, Bass NM. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52: 913–24.
80. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104–12.
81. Tahan V, Canbakan B, Balci H. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology 2008; 55: 1433–8.
82. Cales P, Oberti F, Michalak S. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373–81.
83. Wong VW, Wong GL, Chim AM. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 2008; 103: 1682–8.
84. Qureshi K, Clements RH, Abrams GA. The utility of the 'NAFLD fibrosis score' in morbidly obese subjects with NAFLD. Obes Surg 2008; 18: 264–70.
85. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2010;34:2001-15
86. Rosenberg WM, Voelker M, Thiel R. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704–13.
87. Guha IN, Parkes J, Roderick P. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455–60.
88. Parkes J, Roderick P, Harris S. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245–51.
89. Poynard T, Morra R, Halfon P. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMCGastroenterol 2007; 7: 40.
90. Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointestin Liver Dis 2008; 17: 187–91.
91. Sakugawa H, Nakayoshi T, Kobashigawa K. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11: 255–9.
92. Santos VN, Leite-Mor MM, Kondo M. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005; 38: 747–53.
93. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15: 539–43.
94. de Lédinghen V, Vergniol J. Transient elastography (FibroScan). GastroenterolClin Biol 2008; 32: 58–67.
95. de Lédinghen V, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int 2010; 30: 1043–8.
96. Yoneda M, Yoneda M, Fujita K. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007; 56: 1330–1.
97. Wong VW, Vergniol J, Wong GL. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454–62.
98. de Lédinghen V, Vergniol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices 2010; 7: 811–23.
99. Yin M, Talwalkar JA, Glaser KJ. Assessment of hepatic fibrosis with magnetic resonance elastography. ClinGastroenterol Hepatol 2007; 5: 1207–13.
100. Huwart L, Sempoux C, Vicaut E. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135: 32–40.